German biotech company MorphoSys buys US rival for $1.7B
Germany-based MorphoSys AG said Wednesday that it is buying U.S. rival Constellation Pharmaceuticals Inc. in a deal valuing the biotech company at $1.7 billion.
- Next story France widens COVID vaccine drive to 12 to 18-year-olds
- Previous story Vaccine protection may diminish need for yearly boosters
Explore more
- Gaetz ally plans to plead guilty and cooperate with prosecutors
The ex-Florida tax collector with close ties to Rep. Matt Gaetz is... - Mali’s transitional leaders arrested by military members, says UN mission
Mali’s transitional president and prime minister were arrested Monday and are now... - Aussie kids are some of the least active in the world. We developed a cheap school program that gets results
Australian children are among the least active in the world. In a... - Cultural Diversity and Body Language: Gestures to Avoid Around the World
Cultural diversity enriches our world with a vast array of customs, traditions,... - Biden Wants Leaders to Make Climate Commitments for Earth Day
The administration is closing in on deals with some close allies, but... - When Medicare chips in on hepatitis C treatment for Medicaid patients, everyone wins
Untreated hepatitis C can lead to serious and life-threatening health problems like... - Soundcore Life P3 wireless earbuds offer Active Noise Canceling for under $100
The Life P3 earbuds feature multi-modal active noise cancellation (ANC) technology, wireless... - Nodal and deltoid radiotracer uptake on post-COVID-19 vaccination PET
According to an open-access article in ARRS’ American Journal of Roentgenology (AJR),... - Breast cancer treatments do not increase risk of COVID-19 infection or death
Cancer drugs capable of weakening the body’s immune defenses are no more... - In Colombia’s protests, pandemic pressures collide with an existential reckoning for police
Chief among the many grievances fueling the most widespread wave of protests...